Santen Pharmaceutical Co. Ltd.
(OTC: SNPHY)
|
4:17 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $10.39 | Change: +0.15 | %Change: +1.51% | Volume: 626 |
Open: | $ 10.39 | Volume: | 626 | |
---|---|---|---|---|
High: | $ 10.39 | Yield(%) | 1.77 | |
Low: | $ 10.39 | P/E Ratio (ttm): | 20.54 | |
Dividend ($): | 0.08 | Market Cap ($): | 3.74B | |
EPS ($) | 0.51 | Shares Out: | 363.21M |
% Price Change (last 4 weeks): | -2.58 |
---|---|
% Price Change (last 13 weeks): | 11.11 |
% Price Change (last 26 weeks): | 4.15 |
% Price Change (last 52 weeks): | 19.49 |
% Price Change (year to date): | 3.45 |
Return on Equity (%): | 8.71 |
---|---|
Return on Assets (%): | 6.10 |
Return on Invested Capital (%): | 4.45 |
Gross Profit Margin (%): | 54.27 |
---|---|
Net Profit Margin (%): | 8.82 |
Operating Profit Margin (%): | 17.19 |
|
|
50-day Moving Average: | $7.85 |
---|---|
200-day Moving Average: | $8.32 |
Avg. Daily Vol. (last 50 days): | 1,962 |
Avg. Daily Vol. (last 200 days): | 3,478 |
52-wk high: | $10.85 |
52-wk low: | $8.15 |
Bid: | $n/a |
Ask: | $n/a |
Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.
|
Santen Pharmaceutical Co. Ltd.
Grand Front Osaka Tower A, 25/F 4-20 Ofuka-cho Kita-Ku Osaka OS 530-8552 Phone: 81.6.7664.8621 Fax: 81.6.6321.5082 http://www.santen.co.jp |
Earnings (1year) ($): | 0.51 |
---|---|
Annual Dividend ($): | 0.18 |
Current P/E Ratio (ttm): | 20.54 |
Book Value ($): | 5.57 |
Cash Flow ($): | 0.85 |
Price/Earnings (x): | 20.54 |
---|---|
Price/Sales (x): | 1.73 |
Price/Book (x): | 1.76 |
Price/Cash Flow (x): | 7.20 |
Quick Ratio (x): | 2.08 |
---|---|
Current Ratio (x): | 2.54 |
LT Debt/Equity (x): | 10.59 |
Total Debt/Equity (x): | 11.49 |